| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Forsythoside F targets xanthine oxidase, an enzyme implicated in the production of uric acid. By inhibiting xanthine oxidase, the compound reduces uric acid production and exhibits antihyperuricemic effects. It also targets COX-2, demonstrating preferential COX-2 over COX-1 activity. Forsythoside F also has activity against B16F10 cells.
|
|---|---|
| ln Vitro |
Forsythoside F demonstrates potent in vitro xanthine oxidase inhibitory activity. It has GI50 values of 10-16 µM against B16F10 cells. The compound demonstrates preferential COX-2 over COX-1 activity. These in vitro findings confirm the compound's xanthine oxidase inhibition and its effects on cancer cells.
|
| ln Vivo |
Forsythoside F possesses antihyperuricemic effects in vivo. Its xanthine oxidase inhibitory activity suggests potential in vivo efficacy for reducing uric acid levels in hyperuricemia and gout models. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for Forsythoside F involves measuring its inhibition of xanthine oxidase activity. Xanthine oxidase is incubated with xanthine as a substrate, and the formation of uric acid is monitored spectrophotometrically. Forsythoside F is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for Forsythoside F typically use B16F10 cells to assess its antiproliferative effects. Cells are treated with the compound at various concentrations. Cell viability is measured using standard assays such as MTT or CellTiter-Glo. The GI50 value is determined. COX-2 inhibitory activity can be assessed in cell-based assays.
|
| Animal Protocol |
Forsythoside F has been shown to possess antihyperuricemic effects in vivo. Animal models of hyperuricemia or gout are used to evaluate its efficacy. The compound is administered via oral or parenteral routes. Serum uric acid levels and inflammatory markers are measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Forsythoside F are not extensively documented. As a natural glycoside, it is expected to have moderate bioavailability. Its glycoside moiety may be hydrolyzed in vivo. Further pharmacokinetic studies are necessary to fully characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for Forsythoside F are not extensively available. As a natural compound, it is generally considered to have a favorable safety profile. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
Forsythoside F has been reported to exist in Brandisia hancei, Forsythia koreana, and other organisms with relevant data. See also: Hippophae rhamnoside (note moved to).
Forsythoside F (Arenarioside) is a xanthine oxidase inhibitor with antihyperuricemic effects in vivo. It has GI50 values of 10-16 µM against B16F10 cells and demonstrates preferential COX-2 over COX-1 activity. The compound is used in research on gout and hyperuricemia. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C34H44O19
|
|---|---|
| Molecular Weight |
756.70
|
| Exact Mass |
756.248
|
| CAS # |
94130-58-2
|
| PubChem CID |
6442994
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.65 g/cm3
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
53
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
O([C@@H]1[C@@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)O[C@@H](OCCC2C=CC(O)=C(O)C=2)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C(=O)/C=C/C1C=CC(O)=C(O)C=1
|
| InChi Key |
XPLMUADTACCMDJ-UVQMCPPLSA-N
|
| InChi Code |
InChI=1S/C34H44O19/c1-14-24(41)26(43)28(45)34(50-14)53-31-29(46)33(47-9-8-16-3-6-18(36)20(38)11-16)51-22(13-49-32-27(44)25(42)21(39)12-48-32)30(31)52-23(40)7-4-15-2-5-17(35)19(37)10-15/h2-7,10-11,14,21-22,24-39,41-46H,8-9,12-13H2,1H3/b7-4+/t14-,21+,22+,24-,25-,26+,27+,28+,29+,30+,31+,32-,33+,34-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3215 mL | 6.6076 mL | 13.2153 mL | |
| 5 mM | 0.2643 mL | 1.3215 mL | 2.6431 mL | |
| 10 mM | 0.1322 mL | 0.6608 mL | 1.3215 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
